Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

R. Connor Chick, G. Travis Clifton, Diane F. Hale, Timothy J. Vreeland, Annelies T. Hickerson, Phillip M. Kemp Bohan, Patrick M. McCarthy, Jennifer K. Litton, Gheath Alatrash, Rashmi K. Murthy, Na Qiao, Anne Philips, Jason Lukas, Jarrod P. Holmes, Elizabeth A. Mittendorf, George E. Peoples

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

HER2-targeted therapy has not benefited patients with low levels of HER2 expression; however, combination therapy may be effective. Primary analysis of a phase IIb trial investigating the HER2-derived vaccine nelipepimut-S (NPS) did not benefit the intention-to-treat population, but subset analysis showed a benefit in triple-negative breast cancer (TNBC) patients. The subset analysis of this multicenter, randomized, single-blind, phase IIb trial identified significant improvement in 36-month disease-free survival (DFS) between NPS (n = 55) and placebo (n = 44) in TNBC (HR 0.25, p = 0.01) and those who express HLA-A24 (HR 0.41, p = 0.05). The TNBC cohort demonstrated improved 36-month DFS in those with HER2 1+ expression (HR 0.17, p = 0.01), HLA-A24 positivity (HR 0.08, p < 0.01), or in those who received neoadjuvant chemotherapy (HR 0.21, p < 0.01). NPS vaccination with trastuzumab was associated with improved 36-month DFS among patients with TNBC. The observed benefit to this high-risk subgroup warrants confirmation in a phase III trial.

Original languageEnglish (US)
Article number108679
JournalClinical Immunology
Volume225
DOIs
StatePublished - Apr 2021

Keywords

  • Breast cancer
  • Cancer vaccine
  • Immunotherapy
  • Personalized medicine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer'. Together they form a unique fingerprint.

Cite this